Table 3.
Comparison of biomarker expressions between all ESS and ULMS
| Score | (%) | OR (95% CI) | p Value | Sen (%) | Spe (%) | PPV (%) | NPV (%) | Acc (%) | |
|---|---|---|---|---|---|---|---|---|---|
| (%) ER | <0.0001 | ||||||||
| LMS | ≥8 | 27.30 | 1 | ||||||
| ESS | ≥8 | 92.90 | 34.7 (4.17 to 288) | 46.40 | 97.60 | 92.90 | 72.70 | 76.80 | |
| PR | <0.0001 | ||||||||
| LMS | ≥8 | 24.50 | 1 | ||||||
| ESS | ≥8 | 80.00 | 12.3 (3.45 to 44.1) | 57.10 | 90.20 | 80.00 | 75.50 | 76.80 | |
| CD10 | 0.005 | ||||||||
| LMS | ≥8 | 26.20 | 1 | ||||||
| ESS | ≥8 | 61.50 | 4.51 (1.58 to 12.9) | 59.30 | 75.60 | 61.50 | 73.80 | 69.10 | |
| GEM | 0.043 | ||||||||
| LMS | ≤8 | 17.60 | 1 | ||||||
| ESS | ≤8 | 49.00 | 4.48 (1.14 to 17.6) | 88.90 | 35.90 | 49.00 | 82.40 | 57.60 | |
| h-caldesmon | 0.024 | ||||||||
| LMS | ≤8 | 25.00 | 1 | ||||||
| ESS | ≤8 | 54.30 | 3.56 (1.26 to 10.1) | 70.40 | 60.00 | 54.30 | 75.00 | 64.20 | |
| Trangelin | 0.044 | ||||||||
| LMS | ≤8 | 28.90 | 1 | ||||||
| ESS | ≤8 | 55.20 | 3.02 (1.10 to 8.32) | 59.30 | 69.20 | 57.10 | 71.10 | 65.20 | |
| SMA | 0.045 | ||||||||
| LMS | ≤8 | 30.00 | 1 | ||||||
| ESS | ≤8 | 55.60 | 2.92 (1.06 to 8.06) | 55.60 | 70.00 | 55.60 | 70.00 | 64.20 | |
| ASC1 | 0.29 | ||||||||
| LMS | ≥8 | 22.20 | 1 | ||||||
| ESS | ≥8 | 44.10 | 2.76 (0.53 to 14.4) | 92.90 | 17.50 | 44.10 | 77.80 | 48.50 | |
| Desmin | 0.21 | ||||||||
| LMS | ≤8 | 20.30 | 1 | ||||||
| ESS | ≤8 | 47.10 | 2.04 (0.75 to 5.57) | 61.50 | 56.10 | 47.10 | 69.70 | 58.20 | |
| Stathmin1 | 0.43 | ||||||||
| LMS | ≤8 | 37.00 | 1 | ||||||
| ESS | ≤8 | 47.60 | 1.55 (0.55 to 4.41) | 37.00 | 72.50 | 47.60% | 63.00 | 58.20 |
χ2 test for p values. Score represents composition score based on intensity and % expression.
Acc, accuracy; CD10, cluster of differentiation 10; ER, estrogen receptor; ESS, endometrial stromal sarcoma; GEM, Guanosine-5′- triphosphate (GTP)-binding protein overexpressed in skeletal muscle; and ASC1, solute carrier family 7; LMS, leiomyosarcoma; NPV, negative predictive value; PPV, positive predictive value; PR, progesterone receptor; Sen, sensitivity; SMA, smooth muscle actin; Spe, specificity; ULMS, uterine leiomyosarcoma.